CORCEPT THERAPEUTICS INC responded to SEC staff comments on segment reporting
Letter dated
2025-10-01; published on EDGAR 2026-06-10 — the
SEC releases comment letters only after the review closes.
Evidence
Direction
company to staff
Letter dated
2025-10-01
Published on edgar
2026-06-10
Reviewing
Corcept Therapeutics Incorporated Form 10-K for the Fiscal Year Ended December 31, 2024 File No. 000-50679 Ladies and Gentlemen: This letter responds to the com
Source
Company response to SEC staff (CORRESP)
Topics
Segment reporting
Why
SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.
SEC staff questioned CORCEPT THERAPEUTICS INC's accounting for segment reporting
Letter dated
2025-09-18; published on EDGAR 2026-06-10 — the
SEC releases comment letters only after the review closes.
Evidence
Direction
staff to company
Letter dated
2025-09-18
Published on edgar
2026-06-10
Reviewing
Corcept Therapeutics Inc. Form 10-K for the Fiscal Year Ended December 31, 2024 File No. 000-50679 Dear Atabak Mokari: We have limited our review of your filing
Source
SEC staff comment letter (UPLOAD)
Topics
Segment reporting
Why
SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.